Polymeric nanocarriers for siRNA delivery: Challenges and future prospects

Journal of Biomedical Nanotechnology

Volumn 4, Issue 3, 2008, Pages 258-275

  Cun, Dongmei ^a   Jensen, Linda Boye ^a   Nielsen, Hanne Mørck ^a   Moghimi, Moein ^a   Foged, Camilla ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Delivery; Immune activation; Nanomedicine; Nanoparticles; Polymers; Polyplexes; RNA interference; Safety; siRNA; Toxicity

Indexed keywords

CHEMICAL PROPERTIES; CIVIL AVIATION; CYTOLOGY; DEGRADATION; FUNCTIONAL POLYMERS; INTERNET; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; POLYMERS; RNA; TARGETS; TOXICITY;

DELIVERY; IMMUNE ACTIVATION; NANOMEDICINE; POLYPLEXES; RNA INTERFERENCE; SAFETY; SIRNA;

NUCLEIC ACIDS;

AGENTS ACTING ON THE EYE; ATELOCOLLAGEN; BEVASIRANIB; CAND 5; CHITOSAN; COPOLYMER; CYCLODEXTRIN; DENDRIMER; DRUG CARRIER; FOLIC ACID; MACROGOL; MESSENGER RNA; MICROSPHERE; NANOCAPSULE; NANOCARRIER; NANOPARTICLE; NANOSPHERE; OLIGONUCLEOTIDE; PLASMID DNA; POLY(ISOBUTYLCYANOACRYLATE); POLY(ISOHEXYLCYANOACRYLATE); POLYCATION; POLYELECTROLYTE; POLYETHYLENEIMINE; POLYGLACTIN; POLYGLUTAMIC ACID; POLYLACTIC ACID; POLYLYSINE; POLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BASE PAIRING; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER GENE THERAPY; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPLASM; DIABETIC MACULAR EDEMA; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHYSICAL CHEMISTRY; RETICULOENDOTHELIAL SYSTEM; RETINA MACULA AGE RELATED DEGENERATION; RNA DEGRADATION; RNA INTERFERENCE; TOXICOGENETICS;

EID: 58149190042     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2008.328     Document Type: Conference Paper

References (155)

1. A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806 (1998).
2. M. A. Behlke. Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644 (2006).
3. A. R. de Fougerolles, Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther. 19, 125 (2008).
4. S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494 (2001).
5. S. M. Elbashir, W. Lendeckel, and T. Tuschl, RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188 ( 2001).
6. C. Matranga, Y. Tomari, C. Shin, D. P. Bartel, and P. D. Zamore, Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123, 607 (2005).
7. J. Martinez, A. Patkaniowska, H. Urlaub, R. Luhrmann, and T. Tuschl, Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563 (2002).
8. J. D. Liu, M. A. Carmell, F. V. Rivas, C. G. Marsden, J. M. Thomson, J. J. Song, S. M. Hammond, L. Joshua-Tor, and G. J. Hannon, Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437 (2004).
9. T. I. Orban and E. Izaurralde, Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome. RNA 11, 459 (2005).
10. D. M. Dykxhoorn, D. Palliser, and J. Lieberman, The silent treatment: siRNAs as small molecule drugs. Gene Ther 13, 541 (2006).
11. A. de Fougerolles, H. P. Vornlocher, J. Maraganore, and J. Lieberman, Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6. 443 (2007).
12. D. H. Kim and J. J. Rossi, Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173 (2007).
13. F. M. van de Water, O. C. Boerman, A. C. Wouterse, J. G. P. Peters, F. G. M. Russel, and R. Masereeuw, Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 34, 1393 (2006).
14. D. V. Morrissey, J. A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, V. Jadhav, N. Vaish, S. Zinnen, C. Vargeese, K. Bowman, C. S. Shaffer, L. B. Jeffs, A. Judge, I. MacLachlan, and B. Polisky, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002 (2005).
15. O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, and J. P. Behr, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92, 7297 (1995).
16. D. V. Schaffer, N. A. Fidelman, N. Dan, and D. A. Lauffenburger, Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotechnol. Bioeng. 67, 598 (2000).
17. P. R. Dash, M. L. Read, L. B. Barrett, M. Wolfert, and L. W. Seymour, Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 6, 643 ( 1999).
18. P. Chollet, M. C. Favrot, A. Hurbin, and J. L. Coll, Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J. Gene Med. 4, 84 (2002).
19. T. Merdan, J. Kopecek, and T. Kissel, Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54, 715 (2002).
20. S. C. De Smedt, J. Demeester, and W. E. Hennink, Cationic polymer based gene delivery systems. Pharm. Res. 17, 113 (2000).
21. E. Wagner, M. Zenke, M. Cotten, H. Beug, and M. L. Birnstiel, Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA 87, 3410 (1990).
22. A. Bielinska, J. F. KukowskaLatallo, J. Johnson, D. A. Tomalia, and J. R. Baker, Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24, 2176 (1996).
23. M. X. Tang, C. T. Redemann, and F. C. Szoka, In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjugate Chem. 7, 703 (1996).
24. S. A. Agnihotri, N. N. Mallikarjuna, and T. M. Aminabhavi, Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Controlled Release 100, 5 (2004).
25. I. Fajac, J. C. Allo, E. Souil, M. Merten, C. Pichon, C. Figarella, M. Monsigny, P. Briand, and P. Midoux, Histidylated polylysine as a synthetic vector for gene transfer into immortalized cystic fibrosis airway surface and airway gland serous cells. J. Gene Med. 2, 368 (2000).
26. J. M. Benns, J. S. Choi, R. I. Mahato, J. S. Park, and S. W. Kim, pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer. Bioconjugate Chem. 11, 637 (2000).
27. S. V. Vinogradov, T. K. Bronich, and A. V. Kabanov, Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjugate Chem. 9, 805 (1998).
28. A. U. Bielinska, J. F. KukowskaLatallo, and J. R. Baker, The interaction of plasmid DNA with polyamidoamine dendrimers: mechanism of complex formation and analysis of alterations induced in nuclease sensitivity and transcriptional activity of the complexed DNA. Biochim. Biophys. Acta, Gene Struc. Exp. 1353, 180 (1997).
29. C. Brus, H. Petersen, A. Aigner, F. Czubayko, and T. Kissel, Efficiency of polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradation. Eur. J. Pharm. Biopharm. 57, 427 (2004).
30. W. T. Godbey, M. A. Barry, P. Saggau, K. K. Wu, and A. G. Mikos, Poly(ethylenimine)-mediated transfection: A new paradigm for gene delivery. J. Biomed. Mater. Res. 51, 321 (2000).
31. K. A. Mislick and J. D. Baldeschwieler, Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl. Acad. Sci. USA 93, 12349 (1996).
32. M. Ruponen, S. Ronkko, P. Honkakoski, J. Pelkonen, M. Tammi, and A. Urtti, Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J. Biol. Chem. 276, 33875 (2001).
33. I. Kopatz, J. S. Remy, and J. P. Behr, A model for non-viral gene delivery: through syndecan adhesion molecules and powered by actin. J. Gene Med. 6, 769 (2004).
34. D. J. Gary, N. Puri, and Y. Y. Won, Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Controlled Release 121, 64 (2007).
35. H. Katas and H. O. Alpar, Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Controlled Release 115, 216 (2006).
36. J. Suh, H. J. Paik, and B. K. Hwang, Ionization of poly(ethylenimine) and poly(allylamine) at various phs. Bioorg. Chem. 22, 318 ( 1994).
37. N. D. Sonawane, F. C. Szoka, and A. S. Verkman, Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 278, 44826 (2003).
38. S. Boeckle, K. von Gersdorff, S. van der Piepen, C. Culmsee, E. Wagner, and M. Ogris, Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J. Gene Med. 6, 1102 (2004).
39. T. Bieber, W. Meissner, S. Kostin, A. Niemann, and H. P. Elsasser, Intracellular route and transcriptional competence of polyethylenimine-DNA complexes. J. Controlled Release 82, 441 ( 2002).
40. E. Wagner, Effects of membrane-active agents in gene delivery. J. Controlled Release 53, 155 (1998).
41. P. Erbacher, A. C. Roche, M. Monsigny, and P. Midoux, Putative role of chloroquine in gene transfer into a human hepatoma cell line by DNA lactosylated polylysine complexes. Exp. Cell Res. 225, 186 ( 1996).
42. E. Wagner, C. Plank, K. Zatloukal, M. Cotten, and M. L. Birnstiel, Influenza-virus hemagglutinin-Ha-2 N-terminal fusogenic peptides augment gene-transfer by transferrin polylysine dna complexes-toward a synthetic virus-like gene-transfer vehicle. Proc. Natl. Acad. Sci. USA 89, 7934 (1992).
43. J. Panyam, W. Z. Zhou, S. Prabha, S. K. Sahoo, and V. Labhasetwar, Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16, 1217 ( 2002).
44. D. Goula, C. Benoist, S. Mantero, G. Merlo, G. Levi, and B. A. Demeneix, Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther. 5, 1291 (1998).
45. C. Plank, K. Mechtler, F. C. Szoka, Jr., and E. Wagner, Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery. Hum. Gene Ther. 7, 1437 (1996).
46. P. Opanasopit, M. Nishikawa, and M. Hashida, Factors affecting drug and gene delivery: Effects of interaction with blood components. Crit. Rev. Ther. Drug Carrier Syst. 19, 191 (2002).
47. M. Neu, D. Fischer, and T. Kissel, Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J. Gene Med. 7, 992 (2005).
48. M. Ogris, S. Brunner, S. Schuller, R. Kircheis, and E. Wagner, PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6, 595 (1999).
49. Y. H. Choi, F. Liu, J. S. Kim, Y. K. Choi, J. S. Park, and S. W. Kim, Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier. J. Controlled Release 54, 39 (1998).
50. M. Mannisto, S. Vanderkerken, V. Toncheva, M. Elomaa, M. Ruponen, E. Schacht, and A. Urtti, Structure-activity relationships of poly(L-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J. Controlled Release 83, 169 (2002).
51. S. Katayose and K. Kataoka, Remarkable increase in nuclease resistance of plasmid DNA through supramolecular assembly with poly(ethylene glycol) poly(L-lysine) block copolymer. J. Pharm. Sci. 87, 160 ( 1998).
52. D. Oupicky, M. Ogris, K. A. Howard, P. R. Dash, K. Ulbrich, and L. W. Seymour, Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol. Ther. 5, 463 (2002).
53. P. Erbacher, T. Bettinger, P. Belguise-Valladier, S. M. Zou, J. L. Coll, J. P. Behr, and J. S. Remy, Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI). J. Gene Med. 1, 210 (1999).
54. M. Ogris. G. Walker, T. Blessing, R. Kircheis, M. Wolschek, and E. Wagner, Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J. Controlled Release 91, 173 (2003).
55. G. F. Walker, C. Fella, J. Pelisek, J. Fahrmeir, S. Boeckle, M. Ogris, and E. Wagner, Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol. Ther. 11, 418 (2005).
56. B. Romberg, W. E. Hennink, and G. Storm. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25, 55 (2008).
57. R. M. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang. G. Storm, G. Molema, P. Y. Lu, P. V. Scaria, and M. C. Woodle, Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149 (2004).
58. K. Kunath, T. Merdan, O. Hegener, H. Haberlein, and T. Kissel, Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J. Gene Med. 5, 588 (2003).
59. C. M. Ward, M. Pechar, D. Oupicky. K. Ulbrich, and L. W. Seymour, Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J. Gene Med. 4, 536 (2002).
60. S. S. Diebold, H. Lehrmann, M. Kursa, E. Wagner, M. Cotten, and M. Zenke, Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum. Gene Ther. 10, 775 (1999).
61. A. Sato, S. Kawakami, M. Yamada, F. Yamashita, and M. Hashida, Enhanced gene transfection in macrophages using mannosylated cationic liposome-polyethylenimine-plasmid DNA complexes. J. Drug Targeting 9, 201 (2001).
62. K. Kunath, A. von Harpe, D. Fischer, and T. Kissel, Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J. Controlled Release 88, 159 (2003).
63. S. Ferrari, E. Moro, A. Pettenazzo, J. P. Behr, F. Zacchello, and M. Scarpa, ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther. 4, 1100 (1997).
64. X. Gao and D. Liu, Selective chemical modification on polyethylenimine and its effects on transfection efficiency and cytotoxicity. Mol. Ther. 11, S427 (2005).
65. A. C. R. Grayson, A. M. Doody, and D. Putnam, Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res. 23, 1868 (2006).
66. D. Fischer, Y. X. Li, B. Ahlemeyer, J. Krieglstein, and T. Kissel, In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24, 1121 (2003).
67. S. Akhtar, Beyond delivery. Gene Ther. 13, 739 (2006).
68. A. C. Hunter, Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv. Drug Deliv. Rev. 58, 1523 (2006).
69. A. V. Kabanov, E. V. Batrakova, S. Sriadlbhatla, Z. H. Yang, D. L. Kelly, and V. Y. Alakov, Polymer genomics: Shifting the gene and drug delivery paradigms. J. Controlled Release 101, 259 (2005).
70. S. M. Moghimi, P. Symonds, J. C. Murray, A. C. Hunter, G. Debska, and A. Szewczyk, A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol. Ther. 11, 990 ( 2005).
71. H. Moroson, Polycation-treated tumor cells in vivo and in vitro. Cancer Res. 31, 373 (1971).
72. C. Dufes, W. N. Keith, A. Bilsland, I. Proutski, J. F. Uchegbu, and A. G. Schatzlein, Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res. 65, 8079 (2005).
73. W. S. Meng and L. H. Butterfield, Activation of antigen-presenting cells by DNA delivery vectors. Expert Opin. Biol. Ther. 5, 1019 (2005).
74. S. Werth, B. Urban-Klein, L. Dai, S. Hobel, M. Grzelinski, U. Bakowsky, F. Czubayko, and A. Aigner, A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J. Controlled Release 112, 257 (2006).
75. T. Segura, H. Schmokel, and J. A. Hubbell, RNA interference targeting hypoxia inducible factor 1 alpha reduces post-operative adhesions in rats. J. Surg. Res. 141, 162 (2007).
76. M. Grzelinski, B. Urban-Klein, T. Martens, K. Lamszus, U. Bakowsky, S. Hobel, F. Czubayko, and A. Aigner, RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17, 751 (2006).
77. B. Urban-Klein, S. Werth, S. Abuharbeid, F. Czubayko, and A. Aigner, RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12, 461 (2005).
78. Z. Hassani, G. F. Lemkine, P. Erbacher, K. Palmier, G. Alfama, C. Giovannangeli, J. P. Behr, and B. A. Demeneix, Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. 7, 198 (2005).
79. Y. Lee, H. Mo, H. Koo, J. Y. Park, M. Y. Cho, G. W. Jin, and J. S. Park, Visualization of the degradation of a disulfide polymer, linear poly(ethylenimine sulfide), for gene delivery. Bioconjugate Chem. 18, 13 (2007).
80. M. L. Forrest, J. T. Koerber, and D. W. Pack, A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery. Bioconjugate Chem. 14, 934 (2003).
81. J. Kloeckner, S. Bruzzano, M. Ogris, and E. Wagner, Gene carriers based on hexanediol diacrylate linked oligoethylenimine: effect of chemical structure of polymer on biological properties. Bioconjugate Chem. 17, 1339 (2006).
82. P. J. Tarcha, J. Pelisek, T. Merdan, J. Waters, K. Cheung, K. von Gersdorff, C. Culmsee. and E. Wagner, Synthesis and characterization of chemically condensed oligoethylenimine containing beta-aminopropionamide linkages for siRNA delivery. Biomaterials 28, 3731 (2007).
83. A. Swami, R. K. Kurupati, A. Pathak, Y. Singh, P. Kumar, and K. C. Gupta, A unique and highly efficient non-viral DNA/siRNA delivery system based on PEI-bisepoxide nanoparticles. Biochem. Biophys. Res. Commun. 362, 835 (2007).
84. M. S. Shim and Y. J. Kwon, Controlled delivery of plasmid DNA and siRNA to intracellular targets using ketalized polyethylenimine. Biomacromolecules 9, 444 (2008).
85. M. Thomas, J. J. Lu, Q. Ge, C. C. Zhang, J. Z. Chen, and A. M. Klibanov, Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. USA 102, 5679 (2005).
86. S. R. Mao, M. Neu, O. Germershaus, O. Merkel, J. Sitterberg, U. Bakowsky, and T. Kissel, Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjugate Chem. 17, 1209 (2006).
87. A. Malek, F. Czubayk, and A. Aigner, PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J. Drug Targeting 16, 124 (2008).
88. S. H. Kim, J. H. Jeong, K. C. Cho, S. W. Kim, and T. G. Park, Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J. Controlled Release 104, 223 (2005).
89. S. Zhang, B. Zhao, H. Jiang, B. Wang, and B. Ma, Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Controlled Release 123, 1 (2007).
90. A. Aigner, Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl. Microbiol. Biotechnol. 76, 9 (2007).
91. A. Aigner, Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr. Opin. Mol. Ther. 9, 345 (2007).
92. K. A. Howard and J. Kjems, Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opin. Biol. Ther. 7, 1811 (2007).
93. D. A. Tomalia, Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog. Polym. Sci. 30, 294 (2005).
94. C. C. Lee, J. A. Mackay, J. M. J. Frechet, and F. C. Szoka, Designing dendrimers for biological applications. Nat. Biotechnol. 23, 1517 (2005).
95. S. Svenson and D. A. Tomalia, Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev. 57, 2106 (2005).
96. R. Duncan and L. Izzo, Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57, 2215 (2005).
97. R. Esfand and D. A. Tomalia, Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 6, 427 (2001).
98. D. A. Tomalia, L. A. Reyna, and S. Svenson, Dendrimers as multipurpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 35, 61 (2007).
99. D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, and P. Smith, A new class of polymers-starburst-dendritic macromolecules. Polym. J. 17, 117 ( 1985).
100. M. X. Tang and F. C. Szoka, The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther. 4, 823 (1997).
101. J. H. Zhou, J. Y. Wu, N. Hafdi, J. P. Behr, P. Erbacher, and L. Peng, PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem. Commun. 2364 (2006).
102. X. C. Shen, J. Zhou, X. Liu, J. Wu, F. Qu, Z. L. Zhang, D. W. Pang, G. Quelever, C. C. Zhang, and L. Peng, Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes. Org. Biomol. Chem. 5, 3674 (2007).
103. C. S. Braun, J. A. Vetro, D. A. Tomalia, G. S. Koe, J. G. Koe, and C. R. Middaugh, Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles. J. Pharm. Sci. 94, 423 ( 2005).
104. H. M. Kang, R. DeLong, M. H. Fisher, and R. L. Juliano, Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res. 22, 2099 (2005).
105. T. Tsutsumi, H. Arima, F. Hirayama, and K. Uekama, Potential use of dendrimer/alpha-cyclodextrin conjugate as a novel carrier for small interfering RNA (siRNA). J. Inclusion Phenom. Macrocyclic Chem. 56, 81(2006).
106. T. Tsutsumi, F. Hirayama, K. Uekama, and H. Arima, Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). J. Controlled Release 119, 349 (2007).
107. C. Ramaswamy, T. Sakthivel, A. F. Wilderspin, and A. T. Florence, Dendriplexes and their characterisation. Int. J. Pharm. 254. 17 (2003).
108. I. Gossl, L. J. Shu, A. D. Schluter, and J. P. Rabe, Molecular structure of single DNA complexes with positively charged dendronized polymers. J. Am. Chem. Soc. 124, 6860 (2002).
109. M. A. Kostiainen, J. G. Hardy, and D. K. Smith, High-affinity multivalent DNA binding by using low-molecular-weight dendrons. Angew. Chem. Int. Ed. 44, 2556 (2005).
110. T. Takahashi, J. Hirose, C. Kojima, A. Harada, and K. Kono, Synthesis of poly(amidoamine) dendron-bearing lipids with poly(ethylene glycol) grafts and their use for stabilization of non-viral gene vectors. Bioconjugate Chem. 18, 1163 (2007).
111. T. Takahashi, C. Kojima, A. Harada, and K. Kono, Alkyl chain moieties of polyamidoamine dendron-bearing lipids influence their function as a nonviral gene vector. Bioconjugate Chem. 18, 1349 (2007).
112. Y. Inoue, R. Kurihara, A. Tsuchida, M. Hasegawa, T. Nagashima, T. Mori, T. Niidome, Y. Katayama, and O. Okitsu, Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. J. Controlled Release 126, 59 (2008).
113. K. D. Eom, S. M. Park, H. D. Tran, M. S. Kim, R. N. Yu, and H. Yoo, Dendritic alpha, epsilon-poly(L-lysine)s as delivery agents for antisense oligonucleotides. Pharm. Res. 24, 1581 (2007).
114. R. C. Mundargi, V. R. Babu, V. Rangaswamy, P. Patel, and T. M. Aminabhavi, Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Controlled Release 125, 193 (2008).
115. X. D. Yuan, L. Li, A. Rathinavelu, J. S. Hao, M. Narasimhan, M. He, V. Heitlage, L. Tam, S. Viqar, and M. Salehi, siRNA drug delivery by biodegradable polymeric nanoparticles. J. Nanosci. Nanotechnol. 6, 2821 (2006).
116. N. Murata, Y. Takashima, K. Toyoshima, M. Yamamoto, and H. Okada, Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Controlled Release 126, 246 (2008).
117. J. D. Heidel, Z. P. Yu, J. Y. C. Liu, S. M. Rele, Y. C. Liang, R. K. Zeidan, D. J. Kornbrust, and M. E. Davis, Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA 104, 5715 (2007).
118. D. W. Bartlett and M. E. Davis, Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 99, 975 (2008).
119. D. W. Bartlett, H. Su, I. J. Hildebrandt, W. A. Weber, and M. E. Davis, Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 104, 15549 (2007).
120. D. W. Bartlett and M. E. Davis, Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng. 97, 909 (2007).
121. J. D. Heidel, J. Y. C. Liu, Y. Yen, B. S. Zhou, B. S. E. Heale, J. J. Rossi, D. W. Bartlett, and M. E. Davis, Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res. 13, 2207 (2007).
122. S. Hu-Lieskovan, J. D. Heidel, D. W. Bartlett, M. E. Davis, and T. J. Triche, Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a munne model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984 (2005).
123. J. A. Wolff and D. B. Rozema, Breaking the bonds: non-viral vectors become chemically dynamic. Mol. Ther. 16, 8 (2007).
124. D. B. Rozema, D. L. Lewis, D. H. Wakefield, S. C. Wong, J. J. Klein, P. L. Roesch, S. L. Bertin, T. W. Reppen, Q. Chu, A. V. Blokhin, J. E. Hagstrom, and J. A. Wolff, Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. USA 104, 12982 (2007).
125. D. H. Wakefield, J. J. Klein, J. A. Wolff, and D. B. Rozema, Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group size. Bioconjugate Chem. 16, 1204 (2005).
126. D. Venturoli and B. Rippe, Ficoll and dextran versus globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am. J. Physiol. Ren. Physiol. 288, F605 (2005).
127. K. A. Howard, U. L. Rahbek, X. Liu, C. K. Damgaard, S. Z. Glud, M. O. Andersen, M. B. Hovgaard, A. Schmitz, J. R. Nyengaard, F. Besenbacher, and J. Kjems, RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476 ( 2006).
128. X. D. Liu, K. A. Howard, M. D. Dong, M. O. Andersen, U. L. Rahbek, M. G. Johnsen, O. C. Hansen, F. Besenbacher, and J. Kjems, The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28, 1280 (2007).
129. K. Tahara, T. Sakai, H. Yamamoto, H. Takeuchi, and Y. Kawashima, Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int. J. Pharm. 354, 210 (2008).
130. H. de Martimprey. J. R. Bertrand, A. Fusco, M. Santoro, P. Couvreur, C. Vauthier, and C. Malvy, siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res. 36 (2008).
131. J. Y. Pille, H. Li, E. Blot, J. R. Bertrand, L. L. Pritchard, P. Opolon, A. Maksimenko, H. Lu, J. P. Vannier, J. Soria, C. Malvy, and C. Soria, Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 17, 1019 (2006).
132. W. B. Tan, S. Jiang, and Y. Zhang, Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28, 1565 (2007).
133. F. Delustro, R. A. Condell, M. A. Nguyen, and J. M. Mcpherson, A comparative study of the biologic and immunological response to medical devices derived from dental collagen. J. Biomed. Mater. Res. 20, 109 (1986).
134. K. H. Stenzel, T. Miyata, and A. L. Rubin, Collagen as a biomaterial. Annu. Rev. Biophys. Bioeng. 3, 231 (1974).
135. T. Ochiya, S. Nagahara, A. Sano. H. Itoh, and M. Terada, Biomaterials for gene delivery: Atelocollagen-mediated controlled release of molecular medicines. Curr. Gene Ther. 1, 31 (2001).
136. Y. Takei, K. Kadomatsu, Y. Yuzawa, S. Matsuo, and T. Muramatsu, A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64, 3365 (2004).
137. F. Takeshita, Y. Minakuchi, S. Nagahara, K. Honma, H. Sasaki, K. Hirai, T. Teratani, N. Namatame, Y. Yamamoto, K. Hanai, I. Kato, A. Sano, and T. Ochiya, Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA 102, 12177 (2005).
138. S. Akhtar and I. Benter, Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59, 164 (2007).
139. A. J. Hollins, Y. Omidi, I. F. Benter, and S. Akhtar, Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J. Drug Targeting 15, 83 (2007).
140. Y. Omidi, A. J. Hollins, R. M. Drayton, and S. Akhtar, Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J. Drug Targeting 13, 431 (2005).
141. B. H. Zinselmeyer, S. P. Mackay, A. G. Schatzlein, and I. F. Uchegbu, The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm. Res. 19, 960 (2002).
142. A. D. Judge, V. Sood, J. R. Shaw, D. Fang, K. McClintock, and I. MacLachlan, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457 ( 2005).
143. Q. Ge, L. Filip, A. Bai, T. Nguyen, H. N. Eisen, and J. Chen, Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101, 8676 (2004).
144. M. Cella, M. Salio, Y. Sakakibara, H. Langen, I. Julkunen, and A. Lanzavecchia, Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189, 821 (1999).
145. R. Medzhitov and C. A. Janeway, Jr., Decoding the patterns of self and nonself by the innate immune system. Science 296, 298 (2002).
146. A. D. Judge, G. Bola, A. C. H. Lee, and I. MacLachlan, Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494 (2006).
147. V. Hornung, M. Guenthner-Biller, C. Bourquin, A. Ablasser, M. Schlee, S. Uematsu, A. Noronha, M. Manoharan, S. Akira, A. de Fougerolles, S. Endres, and G. Hartmann, Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasma-cytoid dendritic cells through TLR7. Nat. Med. 11, 263 (2005).
148. M. Schlee, V. Hornung, and G. Hartmann, siRNA and isRNA: Two edges of one sword. Mol. Ther. 14, 463 (2006).
149. M. Sioud, siRNA delivery in vivo. Methods Mol. Biol. 309, 237 ( 2005).
150. S. S. Diebold, C. Massacrier, S. Akira, C. Paturel, Y. Morel, and C. R. E. Sousa, Nucleic acid agonists for toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J. Immunol. 36, 3256 (2006).
151. A. Judge and I. MacLachlan, Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 19, 111 (2008).
152. K. Kariko, M. Buckstein, H. P. Ni, and D. Weissman, Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165 (2005).
153. L. Cekaite, G. Furset, E. Hovig, and M. Sioud, Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J. Mol. Biol. 365, 90 (2007).
154. K. Kariko, P. Bhuyan, J. Capodici, and D. Weissman, Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172, 6545 (2004).
155. M. E. Kleinman, K. Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J. Z. Baffi, R. J. C. Albuquerque, S. Yamasaki, M. Itaya, Y. Z. Pan, B. Appukuttan, D. Gibbs, Z. L. Yang, K. Kariko, B. K. Ambati, T. A. Wilgus, L. A. DiPietro, E. Sakurai, K. Zhang, J. R. Smith, E. W. Taylor, and J. Ambati, Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591 (2008).